Platinum Level Sponsors
In 1923, the founders of Novo Nordisk began a journey to change diabetes. Today, we are thousands of employees across the world with the passion, the skills and the commitment to continue this journey to prevent, treat and ultimately cure diabetes. Novo Nordisk is proud to once again be a Platinum Level Sponsor of the Friends for Life conference, supporting the Family and Friends Banquet and Sports Central. Please come see us at the exhibition to learn more about our type 1 support program, our new camp program and be among the first to learn about the first and only durable insulin pen with 0.5 unit doing and memory function – NovoPen Echo®. To learn more about Novo Nordisk and our support to the type 1 diabetes community visit us at www.novonordisk-us.com.
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research, collaboration and quality manufacturing we strive to make life better for people affected by diabetes and related conditions. We work to deliver breakthrough outcomes through innovative solutions—from medicines and technologies to support programs and more.
Gold Level Sponsors
BD is a leading medical technology company that benefits countless lives worldwide. We advance health by improving the ways that discovery, diagnostics and delivery of care are conducted. With 45,000 employees at work in more than 50 countries, we work in close collaboration with customers and partners to develop innovative products and solutions that enhance outcomes, better manage healthcare delivery costs, increase efficiencies, improve healthcare safety, and expand access to health. Because we’ve been doing this for over 100 years, our portfolio, leadership and partnerships make a difference for global healthcare.
Dexcom, Inc., headquartered in San Diego, CA, is dedicated to developing innovative glucose sensing technology and products to help patients and healthcare providers better manage diabetes. The Dexcom G6™ Continuous Glucose Monitoring (CGM) System does not require fingersticks for calibration or diabetes treatment decisions* and features simple, one-touch sensor insertion. The System provides exceptional accuracy with an overall MARD of 9.0%† and features an Urgent Low Soon alert that can warn users 20 minutes in advance of severe hypoglycemia (55 mg/dL). Dexcom is the only provider of CGM systems indicated for children ages 2 years and older. Please visit www.dexcom.com.
*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
†MARD is a statistical measure of accuracy; the lower the number, the better.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. For more information, visit www.myomnipod.com.
Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. The t:slim X2 pump is capable of remote feature updates using a personal computer. Tandem is based in San Diego, California.
RX ONLY. The t:slim X2 insulin pump, Basal-IQ technology, and Control-IQ technology are intended for single patient use. The t:slim X2 pump, Basal-IQ technology, and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin.
Silver Level Sponsors
The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional nonprofits and other mission-aligned organizations in health, selected place-based initiatives, and education and human services. Since 2008, when the Trust began its active grantmaking, it has committed more than $1 billion. The Helmsley Type 1 Diabetes Program is the largest private foundation funder of T1D-related research, treatment and support services.
Bronze Level Sponsors
Abbott, the worldwide leader in continuous glucose monitoring (CGM), is committed to improving the lives of people with diabetes. The company manufactures, distributes, and markets innovative glucose monitoring systems and other valuable services to help patients and healthcare professionals better manage diabetes care needs. Abbott is pleased to be a sponsor of Friends for Life Orlando Conference. Connect with us at https://freestyle.abbott/cwd, on Facebook at @FreeStyleUS on Instagram at @FreeStyleDiabetes, and on Twitter @FreeStyleDiabet.
Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping improve the lives of people with diabetes by empowering them to take charge of their health. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a simple, positive, daily difference for people with diabetes. Home to the world renowned CONTOUR™ portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products. As a leader in diabetes care and a trusted partner, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy and compliance. Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdin-Diabetes Care products are sold in more than 125 countries. Following the close of the transaction in all countries, Ascensia Diabetes Care will have around 1,400 employees and operations in 38 countries. For further information please visit the Ascensia Diabetes Care website at www.ascensia.com. CONTOUR™ is a registered trademark of Ascensia Diabetes Care Holdings AG.
Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.
Being a global leader in integrated Personalized Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring and digital solutions, Roche Diabetes Care unites with its partners to create patient-centric value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualize relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalized and effective therapy adjustments. For better outcomes and true relief.
As a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Pharmaceuticals, Inc. is dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people
throughout the world. Please visit www.janssen.com for more information.
Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices. Sanofi markets medications for people with type 1 or type 2 diabetes. To follow conversations about life, and life with diabetes connect with us and register for diabetes related articles and lifestyle tips on The DX, like us on Facebook at Sanofi US Diabetes and follow us on Twitter at @diabetes_sanofi.
Friends of CWD
Every day more than 4,000 people are newly diagnosed with diabetes in America. Nearly 115 million Americans have diabetes or prediabetes and are striving to manage their lives while living with the disease. The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For nearly 80 years the ADA has been driving discovery and research to treat, manage and prevent diabetes, while working relentlessly for a cure. We help people with diabetes thrive by fighting for their rights and developing programs, advocacy and education designed to improve their quality of life. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Information is available in English and Spanish. Join the fight with us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).
Beta Bionics is a public benefit corporation and certified B corp. committed to commercializing the iLet® bionic pancreas. We’re a people-focused company, here to serve the wider diabetes community. We want to make a difference and aim to improve the lives of people living with diabetes and hope to reduce the data and decision-making overload that PWD and their caregivers often deal with. To learn more about Beta Bionics, our team and our mission visit us at www.betabionics.com and @BetaBionics on social media.
Founded in February 2015, Beyond Type 1 created and funds a portfolio of programs, technologies and innovations that those living with type 1 diabetes need to manage, live and thrive. Our goal is to highlight the brilliance of those fighting this disease every day while always working toward ensuring a cure is on its way. By establishing a supportive community via powerful social media, people are connected on a global scale in a new way. Our Instagram campaign “Living Beyond,” showcases the age, range and variance of those living their best life with T1D, and our website and social media platforms provide education and support. High profile collaborations and carefully curated special events will provide education and awareness, affording a greater capacity for strategic fundraising. Because our Founders + Founding Friends pay all operational and fundraising expenses, 100% of every dollar raised directly supports the most promising global efforts and programs working to educate, advocate and cure type 1 diabetes. We aim to be provocative, inclusive and disruptive: putting a face on this disease, clearing up misunderstandings about who is affected by T1D and eradicating the stigma that comes from living with a chronic disease. We recognize there is a different narrative to be told: that of a strong empowered community living a powerful life beyond the diagnosis. We also recognize a future free of T1D is possible and we are here to make certain that future materializes. We are here to disrupt diabetes.
One of the first sponsors of Children with Diabetes in their very first year, the Diabetes Research Institute and Foundation are proud to be a part of this important educational and fun event for those affected by diabetes. The mission of the Diabetes Research Institute Foundation is to provide the Diabetes Research Institute with the funding necessary to cure diabetes now. The Diabetes Research Institute, a Center of Excellence at the University of Miami Miller School of Medicine, leads the world in cure-focused research. As the largest and most comprehensive research center dedicated to curing diabetes, the DRI is aggressively working to develop a biological cure by restoring natural insulin production. Researchers have already shown that diabetes can be reversed through islet transplantation, with some study patients living insulin free for more than a decade. The Institute is now building upon these promising outcomes by developing a DRI BioHub, an integrated “mini organ” that mimics that native pancreas, containing thousands of insulin-producing cells that sense blood sugar levels and produce the precise amount of insulin needed in real time. The Diabetes Research Institute and Foundation were created for one reason – to cure diabetes – which is and will continue to be its singular focus until that goal is reached. For the millions of children and adults affected by diabetes, the Diabetes Research Institute is the best hope for a cure. For more information, please visit www.DiabetesResearch.org or call 800-321-3437.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal. In addition to our research funding and leadership, JDRF’s outreach efforts provide practical support and resources for people with T1D and their families every step of the way as they live with T1D. JDRF is proud to partner with Children with Diabetes by sponsoring national conferences and supporting sessions at Friends for Life. For more information, visit the JDRF website at www.jdrf.org, or call 800-533-CURE.
Mallinckrodt is a global specialty pharmaceutical company dedicated to its mission: Managing Complexity. Improving Lives. Our Acquire to Invest business model is applied to therapies that aid healthcare providers in treating patients, including for small, underserved populations who may be challenged by devastating conditions. We invest in areas such as autoimmune and rare diseases; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products. Our investment in these medicines–both in development and after approval–provides
clinical and economic data to help clinicians as they make treatment choices, and in some instances is introducing
long approved medications to a whole new generation of physicians and, ultimately, patients. Learn more at www.mallinckrodt.com.
ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company’s attractive pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market. ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial to assess THR-409 (ocriplasmin) as a potential treatment to prevent the patients with non-proliferative diabetic retinopathy progress to
proliferative diabetic retinopathy. THR-317, a PIGF inhibitor being developed to treat diabetic macular edema, or as a
combination therapy with anti-VEGF treatments, is expected to enter the clinic by year end 2016. In addition, THR-149,
a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos, are in late stage pre-clinical development.